BC Innovations | Dec 22, 2016
Finance

Starting up stem cells

In launching BlueRock Therapeutics with a $225 million series A round, comprehensive IP portfolio and set of strategic partnerships, Versant Ventures and Bayer AG are sending a message they are not only ready to go...
BC Innovations | Sep 24, 2015
Emerging Company Profile

Accelerating stem cells

Growing human pluripotent stem cells on adherent surfaces is inefficient, expensive and often doesn't yield homogeneous cell preparations. Accellta Ltd. has suspension-based, feeder-free methods that produce homogeneous pluripotent stem cells and differentiate them in sufficient...
BC Week In Review | Sep 14, 2015
Company News

Kyoto University, StemCell deal

The university’s iPS Academia Japan Inc. technology transfer arm granted StemCell rights to develop and commercialize technologies for induced pluripotent stem (iPS) cell research. The license will permit StemCell to develop, manufacture and distribute products...
BC Week In Review | Sep 7, 2015
Company News

Minerva Biotechnologies, Kyoto University deal

The university’s technology transfer arm, iPS Academia Japan Inc. , granted Minerva non-exclusive, worldwide rights to develop and commercialize iPS Academia’s induced pluripotent stem (iPS) cell patent portfolio. Minerva will use its primitive stem cell growth...
BC Week In Review | May 26, 2014
Company News

RaQualia, Kyoto University deal

RaQualia and the university's Center for iPS Cell Research and Application (CiRA) and iPS Academia Japan Inc. partnered to identify a small molecule from RaQualia's compound library that could induce differentiation and proliferation of induced...
BC Week In Review | Mar 11, 2013
Company News

Life Technologies, Harvard deal

Life Technologies received exclusive, worldwide rights from Harvard to develop a panel of characterization assays to rapidly evaluate human pluripotent stem (hPS) cells for discovery and translational research applications. Life Technologies said the panel will...
BC Innovations | Feb 7, 2013
Tools & Techniques

Rejuvenating T cells

Two Japanese teams have used induced pluripotent stem cells to regenerate antigen-specific T cells in patients whose immune systems have been depleted. 1,2 Megakaryon Corp. is developing and commercializing the technology of one group to...
BC Week In Review | Sep 24, 2012
Company News

Merck KGaA, Kyoto University deal

Merck's EMD Millipore Corp. division received a non-exclusive, worldwide license to develop and commercialize an induced pluripotent stem (iPS) cell patent portfolio for research applications from the university's technology transfer arm, iPS Academia Japan Inc....
BC Week In Review | Aug 13, 2012
Company News

Lonza, Kyoto University deal

Lonza received a non-exclusive, worldwide license to an induced pluripotent stem cell (iPSC) patent portfolio from the university's technology transfer arm, iPS Academia Japan Inc. Lonza said it will apply the IP to its assay...
BC Week In Review | Jun 25, 2012
Company News

Life Technologies, Kyoto University deal

Life Technologies received a non-exclusive, worldwide license to an induced pluripotent stem cell patent portfolio from the university's technology transfer arm, iPS Academia Japan Inc. Life Technologies said the portfolio allows it to sell IPS-cells...
Items per page:
1 - 10 of 17
BC Innovations | Dec 22, 2016
Finance

Starting up stem cells

In launching BlueRock Therapeutics with a $225 million series A round, comprehensive IP portfolio and set of strategic partnerships, Versant Ventures and Bayer AG are sending a message they are not only ready to go...
BC Innovations | Sep 24, 2015
Emerging Company Profile

Accelerating stem cells

Growing human pluripotent stem cells on adherent surfaces is inefficient, expensive and often doesn't yield homogeneous cell preparations. Accellta Ltd. has suspension-based, feeder-free methods that produce homogeneous pluripotent stem cells and differentiate them in sufficient...
BC Week In Review | Sep 14, 2015
Company News

Kyoto University, StemCell deal

The university’s iPS Academia Japan Inc. technology transfer arm granted StemCell rights to develop and commercialize technologies for induced pluripotent stem (iPS) cell research. The license will permit StemCell to develop, manufacture and distribute products...
BC Week In Review | Sep 7, 2015
Company News

Minerva Biotechnologies, Kyoto University deal

The university’s technology transfer arm, iPS Academia Japan Inc. , granted Minerva non-exclusive, worldwide rights to develop and commercialize iPS Academia’s induced pluripotent stem (iPS) cell patent portfolio. Minerva will use its primitive stem cell growth...
BC Week In Review | May 26, 2014
Company News

RaQualia, Kyoto University deal

RaQualia and the university's Center for iPS Cell Research and Application (CiRA) and iPS Academia Japan Inc. partnered to identify a small molecule from RaQualia's compound library that could induce differentiation and proliferation of induced...
BC Week In Review | Mar 11, 2013
Company News

Life Technologies, Harvard deal

Life Technologies received exclusive, worldwide rights from Harvard to develop a panel of characterization assays to rapidly evaluate human pluripotent stem (hPS) cells for discovery and translational research applications. Life Technologies said the panel will...
BC Innovations | Feb 7, 2013
Tools & Techniques

Rejuvenating T cells

Two Japanese teams have used induced pluripotent stem cells to regenerate antigen-specific T cells in patients whose immune systems have been depleted. 1,2 Megakaryon Corp. is developing and commercializing the technology of one group to...
BC Week In Review | Sep 24, 2012
Company News

Merck KGaA, Kyoto University deal

Merck's EMD Millipore Corp. division received a non-exclusive, worldwide license to develop and commercialize an induced pluripotent stem (iPS) cell patent portfolio for research applications from the university's technology transfer arm, iPS Academia Japan Inc....
BC Week In Review | Aug 13, 2012
Company News

Lonza, Kyoto University deal

Lonza received a non-exclusive, worldwide license to an induced pluripotent stem cell (iPSC) patent portfolio from the university's technology transfer arm, iPS Academia Japan Inc. Lonza said it will apply the IP to its assay...
BC Week In Review | Jun 25, 2012
Company News

Life Technologies, Kyoto University deal

Life Technologies received a non-exclusive, worldwide license to an induced pluripotent stem cell patent portfolio from the university's technology transfer arm, iPS Academia Japan Inc. Life Technologies said the portfolio allows it to sell IPS-cells...
Items per page:
1 - 10 of 17